PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  07:43 2022-08-09 am EDT
49.66 USD   +0.17%
07:36aNovavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
RE
06:54aEU Health Agency Starts Real-time Review of Pfizer-BioNTech's Variant-specific COVID-19 Jab
MT
06:28aEU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Switzerland to Order 3.5 Million Doses of Pfizer-BioNTech, Moderna COVID-19 Jabs for FY23

07/05/2022 | 10:39am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -7.54% 169.3 Delayed Quote.-28.97%
MODERNA, INC. -2.09% 182.94 Delayed Quote.-26.44%
PFIZER, INC. 0.61% 49.57 Delayed Quote.-16.56%
All news about PFIZER, INC.
07:36aNovavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
RE
06:54aEU Health Agency Starts Real-time Review of Pfizer-BioNTech's Variant-specific COVID-19..
MT
06:28aEU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot
RE
02:59aBioPharma Credit To Receive Loan Prepayment Following Pfizer's Takeover Of Global Blood..
MT
01:31aPfizer scoops up Global Blood Therapeutics in $5.4bn deal
AQ
08/08Pfizer, Valneva Commence Late-stage Study of Lyme Disease Vaccine Candidate
MT
08/08Major test of first possible Lyme vaccine in 20 years begins
AQ
08/08Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
BU
08/08Novavax sinks after halving sales forecast on low vaccine demand, supply glut
RE
08/08Viatris, First Solar rise; Tyson Foods, Nvidia fall
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,80x
Yield 2022 3,27%
Capitalization 278 B 278 B -
EV / Sales 2022 2,62x
EV / Sales 2023 3,33x
Nbr of Employees 79 000
Free-Float 58,9%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 49,57 $
Average target price 56,53 $
Spread / Average Target 14,0%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-16.56%278 132
JOHNSON & JOHNSON0.02%447 486
ELI LILLY AND COMPANY9.51%287 428
ROCHE HOLDING AG-16.68%273 741
ABBVIE INC.1.95%248 135
NOVO NORDISK A/S2.04%233 436